PLEASANTON, Calif., March 14, 2019 /PRNewswire/ -- Affirming its role as a global leader in myopia management, CooperVision is voicing strong support for the publication of eight highly-anticipated white papers by the International Myopia Institute (IMI). Released within the past several days, the reports cover a range of topics deemed essential to advancing clinical knowledge and practice relating to stemming the expanding impact of myopia.
The IMI papers are available in a special edition of Investigative Ophthalmology & Visual Science. They are free to download by eye care professionals, researchers and other concerned parties worldwide, consistent with IMI's mission of widely disseminating knowledge about the issue.
"The dozens of eye care professionals, educators, and researchers who constitute the IMI represent some of the most respected minds in our field. Their recommendations are measured and practical, and will no doubt help advance real gains in myopia management and research," said Juan Carlos Aragón, OD, President of the CooperVision Specialty EyeCare Division. "We're proud to be a platinum sponsor of the IMI and applaud its decision to make these white papers available via open access."
The IMI papers were previewed in late 2018 at the American Academy of Optometry Annual Meeting, drawing 400 attendees to the key findings report and panel discussion. Additional presentations are slated for ARVO 2019 (Vancouver) and the International Myopia Conference (Tokyo).
The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 20501, bringing with it near- and long-term health challenges. Not only does it require vision correction, but also increases the likelihood of conditions later in life such as glaucoma, cataract, retinal detachment and myopic maculopathy.
The CooperVision Specialty Eyecare division accelerates eye care professionals' access to advanced products that help improve the way people see each day, with a focus on the development of myopia management approaches and visual correction of irregular corneas. In addition to growing global adoption of the MiSight® 1 day lens2, it encompasses Blanchard Contact Lenses, Paragon Vision Sciences, Procornea, and Soflex, which operate independently while sharing technical, clinical and commercial knowledge, benefitting from CooperVision's global presence and infrastructure.
1 Holden et al, Ophthalmology 2016.
2 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in the United States.
CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc.
email@example.com or +1-585-545-1815